HLS Therapeutics Inc.
HLTRF
$2.96
-$0.33-10.03%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.66M | -22.03M | -24.09M | -27.85M | -27.53M |
| Total Depreciation and Amortization | 22.72M | 24.33M | 27.03M | 29.54M | 31.94M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.80M | 4.00M | 4.84M | 6.50M | 6.34M |
| Change in Net Operating Assets | 1.14M | 2.23M | 4.62M | 4.36M | 5.04M |
| Cash from Operations | 8.00M | 8.53M | 12.40M | 12.55M | 15.79M |
| Capital Expenditure | -15.00K | -16.00K | -16.00K | -43.00K | -41.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.50M | -1.50M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.25M | 13.25M | 13.21M | -148.00K | -148.00K |
| Cash from Investing | 11.74M | 11.73M | 13.19M | -191.00K | -189.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -21.57M | -22.23M | -9.46M | -9.40M | -9.46M |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 0.00 | 134.00K |
| Repurchase of Common Stock | -600.00K | -1.18M | -1.78M | -1.65M | -1.55M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 0.00 | 0.00 | -1.22M | -2.40M |
| Other Financing Activities | -1.19M | -1.19M | -2.55M | -1.89M | -1.36M |
| Cash from Financing | -23.36M | -24.60M | -13.79M | -14.16M | -14.64M |
| Foreign Exchange rate Adjustments | -870.00K | 62.00K | -218.00K | 32.00K | 268.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.50M | -4.27M | 11.58M | -1.77M | 1.23M |